Trials / Completed
CompletedNCT02902679
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
An Open-label Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An oral dose of BMS-986177 administered in End-stage Renal Dysfunction (ESRD) participants before and after a hemodialysis session to evaluate safety, tolerability, and pharmacokinetics in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-09-16
- Last updated
- 2017-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02902679. Inclusion in this directory is not an endorsement.